Business Description
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Business History
Price Overview
Last updated: Jun 27, 2026 8:59am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -121.80
Total Equity: $6.01M
Shares: 98,162
Total Debt: $0.00
Cash: $8.23M
EBITDA: -$11.97M
Total Debt: $0.00
Cash: $8.23M
Revenue: $0.00
Shares: 98,162
Revenue: $0.00
Revenue: $0.00
Revenue: $0.00
Total Equity: $6.01M
Tax Rate: 0.0%
Equity: $6.01M
Total Debt: $0.00
Cash: $8.23M
Current Liabilities: $2.64M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $6.01M
Shares: 98,162
Shares: 98,162
CapEx: -$3,000
Shares: 98,162
Stock Price: $1.82
Net Income: -$11.96M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 27, 2026 4:46am (4h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $22.5M | $0 |
| Cost of Revenue | $73,000 | $50,000 | $57,000 | $4,000 | $4,000 |
| Gross Profit | $-73,000 | $-50,000 | $-57,000 | $-4,000 | $-4,000 |
| Operating Expenses | $9.2M | $2.2M | $11.3M | $8.2M | $12.0M |
| Operating Income | -$9.3M | -$2.2M | -$11.4M | -$8.2M | -$12.0M |
| Net Income | -$9.3M | -$3.2M | -$13.0M | -$8.2M | -$12.0M |
| EBITDA | -$9.2M | -$2.5M | -$10.9M | -$8.2M | -$12.0M |
| EPS | $-2,827.16 | $-47,135.48 | $-140,450.24 | $-1,545.88 | $-121.80 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 27, 2026 4:46am (4h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $90,000 | $9,000 | $1.8M | $5.0M | $8.2M |
| Total Current Assets | $96,000 | $312,000 | $2.9M | $5.6M | $8.6M |
| Total Assets | $218,000 | $383,000 | $3.0M | $5.7M | $8.7M |
| Current Liabilities | $4.9M | $2.0M | $2.7M | $1.6M | $2.6M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.9M | $2.0M | $2.7M | $1.7M | $2.7M |
| Total Equity | -$4.7M | -$1.6M | $259,000 | $4.0M | $6.0M |
| Retained Earnings | -$15.3M | -$18.5M | -$31.5M | -$39.7M | -$51.7M |
Cash Flow (Annual)
Last updated: Jun 27, 2026 4:46am (4h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-847,000 | -$1.1M | -$9.0M | -$8.6M | -$10.2M |
| Capital Expenditure | $0 | $-3,000 | $-8,000 | $0 | $-3,000 |
| Free Cash Flow | $-847,000 | -$1.1M | -$9.0M | -$8.6M | -$10.2M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $-124,000 | $0 | $-1,000 | $-1,000 |
| Net Change in Cash | $-247,000 | $-81,000 | $1.8M | $3.2M | $3.2M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 4:46am (4h ago)| Metric | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$16.2M -$16.7M – -$15.6M
|
$-468,237 $-503,576 – $-432,898
|
$-248,353 $-471,234 – $-25,472
|
$-19,632 $-19,632 – $-19,632
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 27, 2026 4:46am (4h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | -100.0% |
| Gross Profit Growth | +31.5% | -14.0% | +93.0% | +0.0% |
| Operating Income Growth | +75.8% | -408.6% | +27.7% | -45.4% |
| Net Income Growth | +65.4% | -305.3% | +37.0% | -45.7% |
| EBITDA Growth | +72.7% | -333.5% | +24.7% | -46.0% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 4:46am (4h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2025-09-18 | Kelly Leanne | A-Award | 43,222.00 | $1.93 | $83,418 |
| 2025-09-18 | Szekeres David Leslie | A-Award | 39,897.00 | $1.93 | $77,001 |
| 2025-09-18 | Baker David Charles | A-Award | 23,605.00 | $1.93 | $45,558 |
| 2025-09-18 | SIMPSON CAMILLA V | A-Award | 23,605.00 | $1.93 | $45,558 |
| 2025-09-18 | Chaturvedi Vipin | A-Award | 43,222.00 | $1.93 | $83,418 |
| 2025-09-18 | Rongen Roelof | A-Award | 23,605.00 | $1.93 | $45,558 |
| 2025-09-18 | Hertz Walter Marc | A-Award | 103,067.00 | $1.93 | $198,919 |
| 2025-08-26 | Hertz Walter Marc | A-Award | 26,688.00 | $1.41 | $37,630 |
| 2025-08-26 | Szekeres David Leslie | A-Award | 10,276.00 | $1.41 | $14,489 |
| 2025-08-26 | Baker David Charles | A-Award | 5,994.00 | $1.41 | $8,452 |
| 2025-08-26 | Rongen Roelof | A-Award | 5,994.00 | $1.41 | $8,452 |
| 2025-08-26 | Chaturvedi Vipin | A-Award | 11,854.00 | $1.41 | $16,714 |
| 2025-08-26 | SIMPSON CAMILLA V | A-Award | 5,994.00 | $1.41 | $8,452 |
| 2025-08-26 | Kelly Leanne | A-Award | 11,854.00 | $1.41 | $16,714 |
| 2025-08-13 | SIMPSON CAMILLA V | A-Award | 4,527.00 | $1.30 | $5,885 |
| 2025-08-13 | Baker David Charles | A-Award | 4,527.00 | $1.30 | $5,885 |
| 2025-08-13 | Rongen Roelof | A-Award | 4,527.00 | $1.30 | $5,885 |
| 2025-08-13 | Szekeres David Leslie | A-Award | 7,545.00 | $1.30 | $9,809 |
| 2025-01-23 | Kelly Leanne | A-Award | 43,319.00 | $0.69 | $29,704 |
| 2025-01-23 | Chaturvedi Vipin | A-Award | 43,319.00 | $0.69 | $29,704 |
Dividend History (Last 20)
Last updated: Jun 27, 2026 4:46am (4h ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2008-12-29 | $0.00 |
Narrative Economics
market-narrative step).